We will be present at the annual congress of the French Society of Diabetes in Lille from March 28-31. Join us on our stand to find out what's new with the Cellnovo Diabetes Management System. More information: http://www.congres-sfd.com/
The results of the first clinical study were presented and discussed during the 10th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), February 15-18, 2017, in Paris, France. Read the details (in French).
Physical activity (PA) has strong effects on glucose’s dynamics. Therefore, including PA information in artificial pancreas (AP) may improve gylcemia regulation performance. Among a variety of PA indicators, energy expenditure (EE) computed from counts per minute (CPM), is the preferred physiological variable in AP applications. However, current models for converting CPM into EE are mostly linear. In this work we propose a nonlinear model which improves EE estimation, and there may also improve AP performance. This poster was presented at the 10th International Conference on Advanced Technologies & Treatments for Diabetes, February 15-18, 2017, in Paris, France.
Variability of way of life is an issue for good BG control in type 1 diabetes (T1D). Diabeloop is a Closed-loop (CL) system with a MPC algorithm reinforced by a decisional matrix, uploaded on an android smartphone linked to Dexcom CGM and a Cellnovo insulin patch-pump. The primary aim of the study was to compare BG control with Diabeloop CL versus sensor-augmented insulin pump therapy (SAP), in well-educated patients practicing intensive physical exercises repeatedly, or gastronomic dinners or rest, during 3 days. This poster was presented at the 10th International Conference on Advanced Technologies & Treatments for Diabetes, February 15-18, 2017, in Paris, France.
PEPPER (Patient Empowerment through Predictive PERsonalised decision support) is an EU-funded research project to develop a personalised clinical decision support system for Type 1 diabetes self-management. The tool provides insulin bolus dose advice and carbohydrate recommendations, tailored to the needs of individuals. The former is determined by Case-Based Reasoning, an artificial intelligence technique that adapts to new situations according to past experience. The latter uses a model-based approach that also promotes safety by providing glucose alarms, low-glucose insulin suspension and fault detection. This poster was presented at the 10th International Conference on Advanced Technologies & Treatments for Diabetes, February 15-18, 2017, in Paris, France.
Meet the Cellnovo Team at the IPN UK Team Education Day, London, January 10, 2017. This event is a one day session full of educational material on the latest evidence base for diabetes technologies, hot topics such as pregnancy, exercise, transition and sessions dedicated to download interpretation and psychological aspects of diabetes. More information at https://abcd.care/abcd-ipn-uk-team-education-day-london-information
Meet the Cellnovo Team at the IPN UK Team Education Day, Derby, January 6, 2017. This event is a one day session full of educational material on the latest evidence base for diabetes technologies, hot topics such as pregnancy, exercise, transition and sessions dedicated to download interpretation and psychological aspects of diabetes. More information at https://abcd.care/civicrm/event/info?reset=1&id=10
Stephen C Bain. 2016. “The Cellnovo Insulin Delivery System”. European Endocrinology, 2017;13(1): ePub ahead of print.
Professor Bain describes the unique technical and safety features of the Cellnovo mobile-connected diabetes management system, including the ease of use and reliability of insulin dosage delivery, which are critical in the effective management of diabetes when using an insulin delivery system.
Join us for the 10th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2017) taking place in Paris, France, February 15 to 18, 2017. Visit us on our stand to chat with the Cellnovo Team and to discover the latest about the Cellnovo Diabetes Management System.
Diabetes Professional Care is where thousands of healthcare professionals update their knowledge of the key suppliers, solutions and products for effective diabetes care. Cellnovo will be present and we look forward to seeing many of you there.
Join us at the NNF Insulin Pump Service meeting on November 4 to discuss how to develop and deliver an efficient and effective service. Topics include: pump service developments, CGM usage, technology update, and more. Our team will be present and available to answer all your questions about the Cellnovo Diabetes Management System.
Cellnovo will be present at the XVI Latin American Congress on Diabetes (ALAD). Join us at this congress that gathers healthcare professionals dedicated to the study, research and dissemination of problems related to diabetes in Latin America and other countries.
We will be at the Nordic Mobile Healthcare Technology Congress in Stockholm on the 2nd and 3rd of November 2016 to present the Cellnovo Diabetes Management System. Join us to discuss the latest challenges and opportunities in health innovation. This meeting brings together clinicians, the health and social care workforce, policy makers and technology providers to examine how the sector can meet the triple challenge of improving the patient experience, improving health outcomes and reducing the cost of care.
Join us for the 52nd Annual Meeting of the European Association for the Study of Diabetes taking place in Munich, Germany, September 12 to 15, 2016. The EASD Annual Meeting has become the world´s leading international forum for diabetes research and medicine. Visit us on our booth to discover the Cellnovo Diabetes Management System, a breakthrough technology in diabetes care.
Jenna L Bowen and Chris J Allender. 2016. "A Comparative Pulse Accuracy Study Of Two Commercially Available Patch Insulin Infusion Pumps". European Endocrinology, 12(2): ePub ahead of Print.
Patch pumps are a relatively new method of insulin delivery. This study explores the accuracy of patch-pumps by reporting on comparative pulse-accuracy study of two patch pumps. Methods: The accuracy of two patch pumps (Cellnovo, [Cellnovo Ltd., Swansea, UK] and OmniPod® [Ypsomed Ltd, Escrick, UK]) was evaluated micro-gravimetrically. Pulse accuracy was analysed by comparing single and time-averaged pulses for each device.
ATTD attracts an international audience of researchers and clinicians from the fields of diabetes, endocrinology and metabolism, diabetes technology developers as well as general & family medicine practitioners. Join us on our booth to discover the Cellnovo Diabetes Management System.
The Nordic Mobile Health Technology Congress gathers leaders and policy makers from the health industry sector and healthcare institutions to share their experiences and to gain practical guidance on integrating the latest technologies into health and social care. This meeting provided a great opportunity for Cellnovo to take part in a consortium to address some of the key challenges with regard to Mobile Healthcare Technology.